National Eye Institute

NIH trial compares three drugs for diabetic macular edema

Thursday, February 19, 2015

In an NIH-supported clinical trial comparing three drugs for diabetic macular edema (DME), Eylea (aflibercept) provided greater visual improvement, on average, than did Avastin (bevacizumab) or Lucentis (ranibizumab) when vision was 20/50 or worse at the start of the trial. However, the three drugs resulted in similar average improvement when starting vision was 20/40 to 20/32. Investigators found no major differences in the safety of the three drugs. The trial was funded by the National Eye Institute (NEI), part of the NIH.

[Read More]

C-TASC Plans to Double Staff in ‘09

Friday, February 13, 2009

Clinical Trials and Surveys Corp (C-TASC), a clinical trials solutions company, hired three new biostatisticians and plans to double its staff in the next year. The company, which currently employs 35 people, plans to increase to 60 employees by February 2010 in order to keep up with increased demand for its clinical trial services and technologies.

[Read More]